Kinetics of T-Lymphocyte Subsets and Posttransplant Opportunistic Infections in Heart and Kidney Transplant Recipients

2012 ◽  
Vol 93 (1) ◽  
pp. 112-119 ◽  
Author(s):  
Sandra A. Calarota ◽  
Paola Zelini ◽  
Annalisa De Silvestri ◽  
Antonella Chiesa ◽  
Giuditta Comolli ◽  
...  
Medicine ◽  
2015 ◽  
Vol 94 (44) ◽  
pp. e1902 ◽  
Author(s):  
Jang-Hee Cho ◽  
Young-Deuk Yoon ◽  
Hye Min Jang ◽  
Eugene Kwon ◽  
Hee-Yeon Jung ◽  
...  

2014 ◽  
Vol 73 (Suppl 2) ◽  
pp. 980.1-980
Author(s):  
L. Cavagna ◽  
S. Calarota ◽  
R. Caporali ◽  
A. Chiesa ◽  
E. Scorletti ◽  
...  

2018 ◽  
Vol 20 (4) ◽  
pp. e12919 ◽  
Author(s):  
Geovana Basso ◽  
Claudia Rosso Felipe ◽  
Marina Pontello Cristelli ◽  
Juliana Mansur Siliano ◽  
Laila Viana ◽  
...  

2015 ◽  
Vol 69 ◽  
pp. 110-116 ◽  
Author(s):  
Sandra A. Calarota ◽  
Antonella Chiesa ◽  
Annalisa De Silvestri ◽  
Monica Morosini ◽  
Tiberio Oggionni ◽  
...  

Author(s):  
Bhuwania P ◽  

Background: Moderate-risk for Cytomegalovirus (CMV) infection includes patients with donor positive/recipient positive (D+/R+) or donor negative/ recipient positive antibody status (D-/R+). Guidelines recommend high-dose daily Valganciclovir (VGCV) as prophylaxis, which may be due to the paucity of data on the efficacy of every-other-day VGCV. Methods: Our experience of using every-other-day VGCV as a prophylactic strategy in moderate risk Kidney Transplant Recipients (KTR) has been described. We retrospectively reviewed 86 moderate-risk KTR in our institution between 2018 and 2020. CMV infection at 6 months post-transplant was the primary endpoint. Graft survival, biopsy-proven rejection, opportunistic infections, Haematological adverse events, and mortality were also evaluated. Results: CMV infection occurrence at 6 months was zero in our cohort. Incidence of leukopenia was 13%, BPAR-31%, OI-33%, and mortality being 3.5%. Conclusion: Every-Other-Day VGCV dosing can be an effective alternative in moderate risk KTR for CMV prevention.


2018 ◽  
Vol 32 (10) ◽  
pp. e13382
Author(s):  
Marta Bodro ◽  
Maria C. Londoño ◽  
Nuria Esforzado ◽  
Gemma Sanclemente ◽  
Laura Linares ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document